Χώρα: Ιρλανδία
Γλώσσα: Αγγλικά
Πηγή: HPRA (Health Products Regulatory Authority)
TRANEXAMIC ACID
Pharmacia Ireland
500mg/5ml MG/5ml
Solution for Injection
1998-04-01
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Cyklokapron 500mg/5ml, Solution for injection or infusion. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5 ml of the solution contains 500 mg of Tranexamic Acid (100 mg per ml). For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection or infusion. Clear, colourless, aqueous solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Local fibrinolysis In the short term management of haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. General fibrinolysis In the management of haemorrhage complications in association with thrombolytic therapy. In the management of haemorrhage associated with disseminated intravascular coagulation with predominant activation of fibrinolytic system. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Route of administration: Intravenous. _Adults including elderly:_ Acute activation of fibrinolytic mechanisms Local fibrinolysis Upper gastrointestinal haemorrhage 1.0 g (2 ampoules) by slow intravenous injection every six hours for the first three days then 1.0 to 1.5 g orally every six hours for a further three to four days. Prostatectomy 1.0 g by slow intravenous infusion every eight hours for the first three days; thereafter 1 g three to four times daily until macroscopic haematuria is no longer present. As a bladder washout, 1 g is added to 1000 ml of normal saline daily for two to five days after surgery and the bladder is irrigated at a rate of 1 ml/min. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 27/10/2011_ _CRN 2107063_ _page number: 1_ Epistaxis Topical application may be made to the nasal mucosa of patients suffering from epistaxis Διαβάστε το πλήρες έγγραφο